Prospective Validation of the OHI Index

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

NCT Number	NCT05882175
Lead Sponsor	Meir Medical Center Collaborators: Children's Hospital Medical Center, Cincinnati, Rabin Medical Center, Sheba Medical Center, Schneider Children's Medical Center, Israel
Conditions	HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy, Hematologic Neoplasms
Enrollment	300 participants
Start Date	2021-03-03
Primary Completion	2030-03-03 (estimated)
Study Completion	2030-03-03 (estimated)
Updated on ClinicalTrials.gov	2025-05-13